Metastases to the peritoneum represent a serious situation where cancer spreads from its original location to the membrane lining the abdominal cavity. Diagnosing this condition early requires a combination of different medical tests and examinations, as symptoms often don’t appear until the disease has progressed significantly.

Introduction: When to Seek Diagnostic Testing

People who have been diagnosed with cancers that commonly spread to the peritoneum should remain vigilant about potential symptoms and undergo regular monitoring. The peritoneum is a thin membrane that lines the inside of the abdominal cavity and wraps around the organs located there, providing support and containing blood vessels and nerves that supply these organs^[1].

Patients most at risk of developing peritoneal metastases include those with cancers originating in abdominal organs. These primarily include gastric cancer (stomach cancer), ovarian cancer, colorectal cancer, appendix cancer, and pancreatic cancer^[1][2]. When cancer spreads from these organs to the peritoneum, it is generally considered advanced disease and is usually classified as Stage IV in most cases^[1].

It’s important to seek diagnostic testing if you experience specific warning signs. Common symptoms that should prompt medical evaluation include bloating, persistent abdominal pain, nausea and vomiting, constipation, loss of appetite, and unexplained weight loss or weight gain^[4][6]. However, one challenge with peritoneal metastases is that they often don’t cause noticeable symptoms until the condition affects a large portion of the peritoneum^[2].

When symptoms do appear, they are frequently related to complications caused by the cancer spread. One of the most common complications is ascites, which is fluid buildup in the abdomen that causes noticeable swelling and distension^[6]. Other complications include intestinal obstruction, where peritoneal metastases block the intestines, and hydronephrosis, where the kidney tubes (ureters) become blocked, potentially affecting kidney function^[6].

Diagnostic Methods for Identifying Peritoneal Metastases

Diagnosing peritoneal metastases can be challenging because the cancer often spreads across the abdominal lining without forming distinct, easily visible masses. Healthcare providers typically need to combine several different testing approaches to confirm the diagnosis^[8].

Imaging Tests

Imaging tests are usually the first step in looking for suspected peritoneal metastases. These scans help doctors identify visible tumor spread, fluid buildup, or organ involvement^[8]. The most commonly used imaging tests include CT scans (computed tomography), MRI (magnetic resonance imaging), and PET scans (positron emission tomography), or a combination of these^[2][8].

These imaging procedures work by creating detailed pictures of the inside of your body. A CT scan uses X-rays and computer technology to produce cross-sectional images, while an MRI uses magnetic fields and radio waves. A PET scan uses a small amount of radioactive material to highlight areas where cancer cells are more active than normal cells. Together, these scans show how much the cancer has spread throughout the peritoneum^[2].

However, imaging has important limitations. These scans are often not sensitive enough to detect smaller cancers or early peritoneal disease. This means that even if an imaging scan appears normal, it doesn’t completely rule out the presence of peritoneal metastases^[8]. This limitation is why doctors frequently need to use additional diagnostic methods beyond imaging alone.

Blood Tests

Blood tests play a supporting role in diagnosing peritoneal metastases. Your healthcare provider may check your blood for tumor markers, which are substances that tumors release into the bloodstream^[2]. High levels of certain proteins can be a sign of peritoneal metastases and may help guide further testing.

A newer type of blood test called circulating tumor DNA (ctDNA) looks for small pieces of DNA from cancer cells floating in the blood^[8]. This test can help detect peritoneal cancer that doesn’t show up clearly on imaging scans. While promising, this technology represents an emerging area of diagnostics and is used alongside other established testing methods.

Paracentesis (Fluid Sampling)

If you have ascites—fluid buildup in your abdomen—your doctor may perform a procedure called paracentesis^[2]. During this procedure, the provider removes a sample of the fluid from your abdominal cavity. This sample is then sent to a laboratory where specialists examine it under a microscope and test it for signs of cancer cells.

The laboratory can determine whether cancer cells are present in the fluid and can often identify what type of primary cancer has spread. This information is particularly valuable because it confirms not only that peritoneal metastases exist but also helps identify where the cancer originated^[2].

Peritoneal Washing Cytology

Peritoneal washing cytology is a test where fluid from the abdominal cavity is surgically collected during a minor procedure and then examined under a microscope^[8]. Healthcare professionals use this test to check for cancer cells floating in the peritoneal fluid. Even when no visible cancer masses are present during surgery, a positive result from this test is a strong indication that peritoneal spread has occurred^[8].

Staging Laparoscopy

Staging laparoscopy is a minimally invasive surgical procedure that allows doctors to look directly inside the abdominal cavity using a small camera^[8]. During this procedure, the surgeon makes a small incision and inserts a thin tube equipped with a camera and light source. This allows direct visualization of the peritoneum and any tumors present.

This diagnostic approach is especially valuable because it can find peritoneal metastases that are too small to be detected by imaging scans^[8]. During the laparoscopy, the surgeon can also take tissue samples or fluid samples for further laboratory analysis. Because this procedure uses only small incisions rather than large surgical cuts, patients typically recover more quickly than from traditional open surgery.

Biopsy

A biopsy involves removing a small sample of tumor tissue so it can be tested in a laboratory for cancer cells^[2]. This can be done during laparoscopy or through other surgical approaches. The tissue sample is examined by a pathologist—a doctor who specializes in diagnosing diseases by looking at cells and tissues under a microscope.

The biopsy provides definitive confirmation of cancer and gives detailed information about the type of cancer cells present, how aggressive they appear, and where the cancer likely originated. This information is crucial for planning appropriate treatment^[6].

Peritoneal Carcinomatosis Index (PCI)

During the diagnostic process, healthcare providers may use a scoring system called the Peritoneal Carcinomatosis Index, or PCI^[2]. This tool helps doctors map the location of tumors in the abdomen and small intestine, and assigns a score based on the tumor’s size and distribution.

The PCI score helps medical teams understand the extent of disease spread and assists in planning treatment. It also helps doctors determine how likely it is that surgery could successfully remove the visible tumors^[2]. This information is essential when the healthcare team is deciding on the best treatment approach for each individual patient.

Diagnostics for Clinical Trial Qualification

When patients are being considered for participation in clinical trials testing new treatments for peritoneal metastases, they must undergo specific diagnostic evaluations to determine their eligibility. Clinical trials are research studies that test new treatments to determine whether they are safe and effective.

The standard diagnostic methods used to qualify patients for clinical trials include the same imaging tests, blood tests, biopsies, and staging procedures described earlier. However, clinical trials often have very specific requirements regarding what diagnostic information must be documented before a patient can enroll.

Imaging tests such as CT scans, MRI, or PET scans are typically required to establish baseline measurements of tumor size and distribution^[2]. These baseline images are essential because researchers need to compare them with images taken later during the trial to measure whether the experimental treatment is working.

Tissue samples from biopsies are often required for clinical trials because researchers may need to test the tumor tissue for specific genetic markers or protein expressions. Some experimental treatments only work against tumors with particular characteristics, so confirming these characteristics through laboratory testing of biopsy samples is necessary before enrollment^[2].

Blood tests establishing tumor marker levels and overall health status are standard requirements for most clinical trials. Trial protocols specify exactly which blood tests must be performed and what the acceptable ranges are for various measurements. This ensures that patients entering the study have similar disease characteristics, which makes the trial results more reliable and interpretable.

The Peritoneal Carcinomatosis Index may be specifically required by some clinical trials that are testing surgical treatments combined with chemotherapy. Trials often specify a maximum PCI score for eligibility, as patients with very extensive disease may not benefit from certain surgical approaches^[2].

Patients being considered for clinical trials may also undergo staging laparoscopy if their imaging tests don’t provide complete information about the extent of peritoneal metastases^[8]. This ensures that trial participants truly have the disease characteristics the study is designed to investigate and haven’t been misclassified based on less accurate diagnostic methods.

Some trials require confirmation that the primary cancer site has been identified and documented through biopsy. Since peritoneal metastases can arise from various organ cancers, and different primary cancers may respond differently to treatments, clinical trials often specify which types of primary cancers are eligible for the study.

Performance status evaluations are another diagnostic criterion for clinical trial qualification. Doctors assess how well patients can perform daily activities and how the cancer affects their overall functioning. This assessment helps determine whether patients are healthy enough to tolerate experimental treatments and complete the trial requirements.